Search results for "cumulative"

showing 10 items of 299 documents

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct

Epidemiology of Overuse Injuries in Youth Team Sports: A 3-year Prospective Study

2017

AbstractProspective studies on overuse injuries and their impact on athletic training among youth team sports are scarce. The purpose of this study was to investigate the incidence, severity and player related risk factors of overuse injuries among young (12–20 years) basketball and floorball players. A total of 387 players participated in a 3-year prospective study. Each player completed a baseline questionnaire regarding their background information. Overuse injuries that prevented players to fully or partly participate in their regular training were collected. In all, 204 overuse injuries were registered (injury incidence 1.51 injuries/1 000 h of exposure; 95% CI 1.35–1.78). Most of the …

MaleBackground informationmedicine.medical_specialtyBasketballAdolescentCumulative Trauma DisordersPhysical Therapy Sports Therapy and RehabilitationBasketballRate ratioYoung Adult03 medical and health sciencesAthletic training0302 clinical medicineRisk FactorsEpidemiologymedicineHumansOrthopedics and Sports MedicineProspective StudiesYoung adultChildProspective cohort studyFinland030222 orthopedicsbusiness.industryIncidenceIncidence (epidemiology)Youth Sports030229 sport sciencesAthletic InjuriesPhysical therapyFemalebusinesshuman activitiesInternational Journal of Sports Medicine
researchProduct

Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

2017

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 6…

MaleCancer Research0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesHydroxyureaCumulative incidenceTreatment FailureEnzyme InhibitorsLenalidomideAged 80 and overCytarabineAnemiaMiddle AgedThalidomideMelodysplastic syndromeSurvival RateLeukemia Myeloid AcuteOncologyInternational Prognostic Scoring System030220 oncology & carcinogenesisRetreatmentAzacitidineCyclosporineDisease ProgressionChromosomes Human Pair 5FemaleChromosome DeletionErythrocyte Transfusionmedicine.drugmedicine.medical_specialtyMelodysplastic syndrome erytropoiesis stimulating agents 5q-erytropoiesis stimulating agentsDecitabineAntineoplastic AgentsTretinoinDecitabineLower risk5q-Arsenic03 medical and health sciencesInternal medicinemedicineHumansImmunologic FactorsSurvival rateAgedAntilymphocyte SerumRetrospective StudiesLenalidomidebusiness.industryValproic AcidMyelodysplastic syndromesRetrospective cohort studymedicine.diseaseMyelodysplastic SyndromesHematinicsPhysical therapybusiness030215 immunology
researchProduct

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

2015

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-u…

MaleCancer ResearchInternational CooperationGastroenterologyArsenicalsEuropean LeukemiaNetchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteRecurrence80 and overCumulative incidenceProspective StudiesRegistriesLeukocytosisArsenic trioxideChildAged 80 and overPromyelocyticLeukemiaCell DifferentiationOxidesHematologyMiddle AgedEuropeLeukemiaTreatment OutcomeOncologyChild PreschoolFemalemedicine.symptomAdultAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentAntineoplastic AgentsAcuteDisease-Free SurvivalYoung AdultInternal medicinemedicineHumansAutologous transplantationPreschoolAgedbusiness.industrymedicine.diseaseSurgeryTransplantationAdolescent; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Arsenicals; Cell Differentiation; Child; Child Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia Promyelocytic Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young AdultchemistrybusinessSettore MED/15 - Malattie del SangueLeukemia
researchProduct

Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry.

2008

Abstract The incidence of soft tissue sarcoma (STS) in Europe is increasing, but it is unclear whether this increase can also be seen in Germany. We analysed the heterogeneous group of STS recorded to the German Childhood Cancer Registry (GCCR) between 1985 and 2004 with respect to incidence data. Age-specific, age-standardised and cumulative incidence rates were calculated. Additionally, the average annual percent change (AAPC), derived from a Poisson regression model, was estimated, using time in years as the explanatory, continuous variable. Two thousand sixty-one children were diagnosed at a median age of 72 months. Most common are rhabdomyosarcomas (RMS) (n = 1202) and fibrosarcomas (n…

MaleCancer ResearchPediatricsmedicine.medical_specialtyTime FactorsFibrosarcomasymbols.namesakeAge DistributionGermanyEpidemiologyRhabdomyosarcomaMedicineHumansCumulative incidencePoisson regressionChildChildhood Cancer Registrybusiness.industryIncidence (epidemiology)Soft tissue sarcomaSarcomamedicine.diseaseAnnual Percent ChangeCancer registryOncologyChild PreschoolsymbolsFemalebusinessEpidemiologic MethodsEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA a…

2019

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients wi…

MaleCancer Researchcomplex karyotypeANTHRACYCLINE MONOCHEMOTHERAPYmedicine.medical_treatmentAbnormal KaryotypechemotherapyGastroenterologyLeukocyte Count0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsPROGNOSTIC-SIGNIFICANCECumulative incidenceATRAChildIn Situ Hybridization FluorescenceAged 80 and overrelapsePETHEMAIncidence (epidemiology)ADDITIONAL CHROMOSOME-ABNORMALITIESAge FactorsHematologyMiddle AgedPrognosisARSENIC TRIOXIDEFLT3 MUTATIONSLeukemiaTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisCytogenetic AnalysisFemaleAdultAcute promyelocytic leukemiamedicine.medical_specialtyCYTOGENETIC CHANGESAdolescentYoung Adult03 medical and health sciencesInternal medicineStatistical significanceComplex KaryotypemedicineHumansClinical significanceAgedCONSOLIDATION THERAPYChromosome AberrationsChemotherapybusiness.industrymedicine.diseaseRISK-ADAPTED TREATMENTTRANS-RETINOIC ACIDATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapsebusinessprognostic030215 immunologyLeukemia & Lymphoma
researchProduct

The association between new onset atrial fibrillation and incident cancer—A nationwide cohort study

2018

A recent analysis showed an association with new onset atrial fibrillation (NOAF) and incident cancer among women. We aimed to examine the risk of cancer among patients with NOAF in general population. A retrospective cohort of 5130 patients with NOAF was identified from a random sample of one million subjects between 2005 and 2010 from Taiwan National Health Insurance Research Database. The standard incidence ratio of incident cancer and hazard ratios were calculated by modeling cumulative incidence with competing risk of death. During a mean follow-up duration of 3.4 years, 330 patients developed cancer. The standard incidence ratio of all malignancies was 1.41 (95% confidence interval 1.…

MaleEconomicslcsh:MedicineSocial Sciences030204 cardiovascular system & hematologyVascular MedicineBrain Ischemia0302 clinical medicineRisk FactorsNeoplasmsEpidemiology of cancerAtrial FibrillationMedicine and Health SciencesGenitourinary CancersCumulative incidence030212 general & internal medicinelcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryCancer Risk FactorsIncidenceHazard ratioAge FactorsMiddle AgedStrokeOncologyNeurologyFemaleArrhythmiaCohort studyResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesUrologyPopulationCardiology03 medical and health sciencesBreast cancerHealth EconomicsSex FactorsDiagnostic MedicineInternal medicinemedicineCancer Detection and DiagnosisHumanseducationIschemic StrokeAgedColorectal Cancerbusiness.industrylcsh:RCancerCancers and NeoplasmsRetrospective cohort studymedicine.diseaseHealth CareWomen's Healthlcsh:QbusinessHealth InsuranceFollow-Up StudiesPLoS ONE
researchProduct

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct

General oxidative stress during doxorubicin-induced cardiotoxicity in rats: Absence of cardioprotection and low antioxidant efficiency of alpha-lipoi…

2012

International audience; To evaluate the effects of alpha-lipoic acid (AL) in a model of doxorubicin (DOX)-induced cardiotoxicity, male Wistar rats were treated with DOX (1 mg/kg/d; 10 d) in combination or not with AL (50 mg/kg/d; 15 d). Plasma oxidative stress was determined by hydroperoxides (ROOH) and the ascorbyl radical/ascorbate ratio. One and two months later, the functional parameters of the hearts were determined in vivo by catheterization and cardiac oxidative stress was assessed by malonedialdehyde (MDA) and O₂*⁻ (dihydroethidium fluorescence) content in tissue. After two months, body weight was higher in the DOX-AL group than in DOX (+16%), but this was due to ascites. Histologic…

MaleMESH : Oxidative StressAntioxidantmedicine.medical_treatmentMESH : HematocritMESH : Thioctic AcidBiochemistryAntioxidants0302 clinical medicineSuperoxidesAscitic FluidMESH: AnimalsMESH : Body WeightComputingMilieux_MISCELLANEOUS0303 health sciencesThioctic AcidCumulative doseMESH: Heart DiseasesHeartGeneral Medicine3. Good healthMESH: Ascitic Fluid[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisMESH : Ascitic FluidMESH: Hydrogen PeroxideMESH : AntioxidantsMESH: Thioctic Acidmedicine.medical_specialtyCardiotonic AgentsCardiotoxinsMESH: Hematocrit03 medical and health sciencesMESH: Doxorubicin[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoRats Wistar[ SDV ] Life Sciences [q-bio]MyocardiumMESH: AntioxidantsHydrogen PeroxideMESH: Cardiotonic AgentsMESH : Organ SizeMESH: Body WeightMESH: Heartcarbohydrates (lipids)EndocrinologyMESH: LiverMESH : SuperoxidesMESH: Organ Size[SDV]Life Sciences [q-bio]MESH : Cardiotonic AgentsAscorbic AcidMESH: Superoxidesmedicine.disease_causeMESH: EatingEatingpolycyclic compoundsMESH : MyocardiumMESH: Thiobarbituric Acid Reactive SubstancesMESH: Ascorbic AcidAntibiotics AntineoplasticMESH: Oxidative StressChemistryMESH : RatsOrgan SizeMESH : Antibiotics Antineoplastic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBiochemistryHematocritLiverMESH : Cardiotoxinsmedicine.drugMESH : EatingMESH: MyocardiumHeart DiseasesMESH: RatsMESH : MaleMESH : Thiobarbituric Acid Reactive SubstancesMESH : Rats WistarThiobarbituric Acid Reactive SubstancesContractilityMESH : HeartInternal medicinemedicineTBARSAnimalsMESH : DoxorubicinDoxorubicinMESH: Antibiotics AntineoplasticMESH : Ascorbic Acid030304 developmental biologyCardiotoxicityBody WeightMESH : LiverMESH : Heart DiseasesMESH: Rats WistarMESH: MaleRatsOxidative StressMESH: CardiotoxinsDoxorubicinMESH : AnimalsMESH : Hydrogen PeroxideOxidative stress
researchProduct